Comparing Platelet-rich Plasma and Steroid Injections for Frozen Shoulder Treatment

A study to compare efficacy of intra-articular platelet rich plasma versus corticosteroid injection in treatment of adhesive capsulitis of shoulder - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087783

Enrollment

Registered

2025-05-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M750- Adhesive capsulitis of shoulder

Interventions

Intervention1: Platelet rich plasma: Platelet rich plasma will be prepared by collecting 20 ml of sample of venous blood from the patient’s cubital vein under sterile aseptic precautions and it will b

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically stage 2 Adhesive capsulitis with duration of symptoms more than 3 months, but less than 9 months. 1. Patients with a normal radiograph finding of the affected shoulder. 2. Moderate to severe pain (visual analogue scale score more than 50) 3. Limitations of both active and passive movements of the glenohumeral joint of 25 percent or more in 2 or more directions (abduction, flexion, external rotation, internal rotation) as compared to contra lateral shoulder. 4. If bilateral shoulder is involved and qualify inclusion, only the dominant arm was considered for intervention.

Exclusion criteria

Exclusion criteria: 1. Patients with secondary adhesive capsulitis (inflammatory joint disease, structural or functional limitations in the shoulder joint from any other pre-existing musculoskeletal pathology or neurologic disorder). 2. Anaemia (haemoglobin less than 9) 3. Uncontrolled diabetes mellitus. 4. Poor cognitive status. 5. People who are unable to follow exercise program. 6. Patient who had previously undergone any intra articular injection or invasive procedure or surgery in the shoulder joint.

Design outcomes

Primary

Measure	Time frame
Severity of pain in VAS ScaleTimepoint: Data will be collected at Day 0, 3rd Week, 6th Week and 12th Week	—

Secondary

Measure	Time frame
1. Limitations in activity of daily living (ADL) in shoulder pain and disability index (SPADI) score. 2. Range of motion of shoulder.Timepoint: Data will be collected at Day 0, 3rd Week, 6th Week and 12th Week	—

Countries

India

Contacts

Public ContactDr Pankaj Kumar Mandal

R G Kar Medical College and Hospital

rehabyouall@gmail.com9433915696

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026